FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY
FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY
复制标题
DOI：
10.1097/iae.0000000000003196
复制
发表时间：
2021-11-01
影响因子：
3.3
通讯作者：
Kusaka, Shunji
中科院分区：
文献类型：
--
作者：
Iwahashi, Chiharu;Utamura, Shoko;Kusaka, Shunji
目的：探讨玻璃体内注射抗血管内皮生长因子（抗VEGF治疗）治疗早产儿视网膜病变（ROP）的疗效和危险因素。方法：我们回顾性分析了2012年1月至2018年2月期间接受抗VEGF治疗的43例1型ROP或更严重患者的80只眼。将患者分为贝伐单抗0.25 mg组（IVB组，37只眼）和雷珠单抗0.25 mg组（IVR组，43只眼）。结果：抗血管内皮生长因子治疗后ROP活性均降低，但有14眼（17.5%）出现再激活。IVB组和IVR组的再激活率分别为13.5%和20.9%（P = 0.556）。多因素Logistic回归分析显示，月经后年龄
Purpose: To investigate the efficacy and risk factors of intravitreal antivascular endothelial growth factor injection (anti-VEGF therapy) for retinopathy of prematurity (ROP).Methods: We retrospectively reviewed 80 consecutive eyes of 43 patients with Type 1 ROP or worse who received anti-VEGF therapy during January 2012-February 2018. Patients were divided into those who were injected with 0.25 mg of bevacizumab (IVB group, 37 eyes) and 0.25 mg of ranibizumab (IVR group, 43 eyes). Serum VEGF concentrations of 18 patients were measured before and after IVR.Results: Antivascular endothelial growth factor injection therapy reduced ROP activity in all eyes; however, 14 eyes (17.5%) exhibited reactivation. The reactivation rates of the IVB and IVR groups were 13.5% and 20.9%, respectively (P = 0.556). Multivariate logistic regression analysis showed that postmenstrual age